PUMA BIOTECHNOLOGY, INC.
PBYIPuma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.
Drugs in Pipeline
10
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
7wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
lapatinib
HER2+ Metastatic Breast Cancer (MBC)
Capecitabine
Breast Cancer
Neratinib
Advanced Breast Cancer
HKI-272
Carcinoma, Non-Small-Cell Lung
Loperamide
Early Stage HER2+ Breast Cancer
vinorelbine
Breast Cancer
Trastuzumab
Breast Cancer
Alisertib
Hormone Receptor Positive HER-2 Negative Breast Cancer
Temsirolimus
Breast Cancer
Paclitaxel
Advanced Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
lapatinib | Phase 3 | HER2+ Metastatic Breast Cancer (MBC) | - | - |
Capecitabine | Phase 3 | Breast Cancer | - | - |
Neratinib | Phase 3 | Advanced Breast Cancer | - | - |
HKI-272 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Loperamide | Phase 2 | Early Stage HER2+ Breast Cancer | - | |
vinorelbine | Phase 2 | Breast Cancer | - | |
Trastuzumab | Phase 2 | Breast Cancer | - | - |
Alisertib | Phase 2 | Hormone Receptor Positive HER-2 Negative Breast Cancer | - | - |
Temsirolimus | Phase 2 | Breast Cancer | - | Patent 2032 |
Paclitaxel | Phase 2 | Advanced Breast Cancer | - | Patent 2034 |
Breast Cancer
4 drugs in this indication
Advanced Breast Cancer
2 drugs in this indication
Early Stage HER2+ Breast Cancer
1 drug in this indication
HER2+ Metastatic Breast Cancer (MBC)
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Hormone Receptor Positive HER-2 Negative Breast Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)